Kristen Ward

AXS-05: an investigational treatment for Alzheimer's disease-associated agitation.

Expert Opinion on Investigational Drugs August 2022 Kristen Ward, Leslie Citrome

Agitation is common in patients with Alzheimer's disease (AD). Although nonpharmacologic de-escalation strategies are recommended as first-line treatment, medication is often needed to treat agitation. Currently, there are no FDA-approved medications for this indication. Psychotropics used to treat agitation include antipsychotics, which are notable for their efficacy but also their potential...